Abstract
Background
Experience with nasogastric administration of oral DDAVP [desamino-d-arginine-8-vasopressin] lyophilisate (ODL) for central diabetes insipidus (CDI) in disabled children with swallowing coordination difficulties is limited.
Objective
We aimed to assess the safety and efficacy of nasogastric use of ODL in disabled children with CDI. Time to serum sodium normalisation was compared with that of children with normal intellect and CDI treated with sublingual DDAVP.
Methods
Clinical, laboratory and neuroimaging characteristics were evaluated for 12 disabled children with CDI treated with ODL through nasogastric tube at Dr Behcet Uz Children's Hospital, Turkey, between 2012 and 2022.
Results
Six boys and six girls with a mean (±SD) age of 43 (± 40) months were evaluated. These children (mean [±SD] weight standard deviation score [SDS] − 1.2 ± 1.7; mean [±SD] height SDS − 1.3 ± 1.4) presented with failure to thrive, irritability, prolonged fever, polyuria and hypernatraemia (mean serum sodium 162 [±3.6] mEq/L). At diagnosis, mean serum and urine osmolality were 321 (± 14) mOsm/kg and 105 (± 7.8) mOsm/kg, respectively. Arginine vasopressin (AVP) levels were undetectable (< 0.5 pmol/L) at diagnosis in all patients. Nasogastric tube administration of DDAVP lyophilisate (120 µg/tablet) dissolved in water (10 mL) was commenced at a dose of 1–5 µg/kg/day in two divided doses together with controlled water intake to avoid hyponatraemia. The frequency and dose of DDAVP were titrated based on urine output and serum sodium concentration. Serum sodium declined at a rate of 0.11 ± 0.03 mEq/L/h and reached normal range in a mean duration of 174 ± 46.5 h. Serum sodium declined faster in children with normal intellect and CDI treated with sublingual DDAVP (1.28 ± 0.39 mEq/L/h; p = 0.0003). Three disabled children needed rehospitalisation because of hypernatraemia due to unintentional DDAVP omission by caregivers. No episode of hyponatraemia was observed. Weight gain and growth were normal during the median (± interquartile range) follow-up duration of 32 ± 67 months.
Conclusions
Nasogastric administration of oral DDAVP lyophilised formulation was safe and effective in the treatment of CDI in disabled children in this small retrospective series.
Similar content being viewed by others
References
Robertson G. Posterior pituitary. 4th ed. McGraw-Hill Education/Medical; 2001.
Di Iorgi N, Morana G, Napoli F, Allegri AE, Rossi A, Maghnie M. Management of diabetes insipidus and adipsia in the child. Best Pract Res Clin Endocrinol Metab. 2015;29(3):415–36.
Di Iorgi N, Napoli F, Allegri AE, Olivieri I, Bertelli E, Gallizia A, et al. Diabetes insipidus–diagnosis and management. Horm Res Paediatr. 2012;77(2):69–84.
Atasay B, Berberoglu M, Gunlemez A, Evliyaoglu O, Adiyaman P, Unal S, et al. Management of central diabetes insipidus with oral desmopressin in a premature neonate. J Pediatr Endocrinol Metab. 2004;17(2):227–30.
Lee YJ, Huang FY, Shen EY, Kao HA, Ho MY, Shyur SD, et al. Neurogenic diabetes insipidus in children with hypoxic encephalopathy: six new cases and a review of the literature. Eur J Pediatr. 1996;155(3):245–8.
Molnar Z, Sotiridou E, Dixon H, Ogilvy-Stuart A. Transient diabetes insipidus in a very-low-birthweight preterm infant with intraventricular haemorrhage. Acta Paediatr. 2012;101(9):e389–90.
Rivas-Crespo MF, Minones-Suarez L, Susana Serrano GG. Rare neonatal diabetes insipidus and associated late risks: case report. BMC Pediatr. 2012;12:56.
De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, et al. Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol. 2011;185(6):2308–13.
Osterberg O, Savic RM, Karlsson MO, Simonsson US, Norgaard JP, Walle JV, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46(10):1204–11.
Cheetham T, Baylis PH. Diabetes insipidus in children: pathophysiology, diagnosis and management. Paediatr Drugs. 2002;4(12):785–96.
Raine JE, Donaldson MD, Gregory JW, Vliet GV. Practical endocrinology and diabetes in children. 3rd ed. Oxford: Wiley-Blackwell; 2011.
Bajpai A, Kabra M, Menon PS. Central diabetes insipidus: clinical profile and factors indicating organic etiology in children. Indian Pediatr. 2008;45(6):463–8.
Liu SY, Tung YC, Lee CT, Liu HM, Peng SF, Wu MZ, et al. Clinical characteristics of central diabetes insipidus in Taiwanese children. J Formos Med Assoc. 2013;112(10):616–20.
Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, Zecca S, et al. Central diabetes insipidus in children and young adults. N Engl J Med. 2000;343(14):998–1007.
Santiprabhob J, Likitmaskul S, Boonyasiri A, Boonsathorn S, Buddawong T. Etiologies of central diabetes insipidus in Thai children. J Pediatr Endocrinol Metab. 2005;18(7):653–61.
Masera N, Grant DB, Stanhope R, Preece MA. Diabetes insipidus with impaired osmotic regulation in septo-optic dysplasia and agenesis of the corpus callosum. Arch Dis Child. 1994;70(1):51–3.
Mavinkurve M, McGrath N, Johnston N, Moloney S, Murphy NP, Hawkes CP. Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus. J Pediatr Endocrinol Metab. 2017;30(6):623–8.
Smego AR, Backeljauw P, Gutmark-Little I. Buccally administered intranasal desmopressin acetate for the treatment of neurogenic diabetes insipidus in infancy. J Clin Endocrinol Metab. 2016;101(5):2084–8.
Ooi HL, Maguire AM, Ambler GR. Desmopressin administration in children with central diabetes insipidus: a retrospective review. J Pediatr Endocrinol Metab. 2013;26(11–12):1047–52.
Arima H, Oiso Y, Juul KV, Norgaard JP. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. Endocr J. 2013;60(9):1085–94.
Kataoka Y, Nishida S, Hirakawa A, Oiso Y, Arima H. Comparison of incidence of hyponatremia between intranasal and oral desmopressin in patients with central diabetes insipidus. Endocr J. 2015;62(2):195–200.
Werny D, Elfers C, Perez FA, Pihoker C, Roth CL. Pediatric central diabetes insipidus: brain malformations are common and few patients have idiopathic disease. J Clin Endocrinol Metab. 2015;100(8):3074–80.
Korkmaz HA, Kapoor RR, Kalitsi J, Aylwin SJ, Buchanan CR, Arya VB. Central diabetes insipidus in children and adolescents: twenty-six year experience from a single centre. Int J Endocrinol. 2022;2022:9397130.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Conflict of interest
The authors declare there is no conflict of interest in this paper.
Availability of Data and Material
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics Approval
The study was approved by the Research Ethics Board of Dr Behcet Uz Children’s Hospital in Turkey. The authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
Consent to Participate
Written informed consent was obtained from parents of all participants.
Consent for Publication
The authors confirm that consent of parents of all participants was obtained to publish the data.
Code Availability
Not applicable.
Authors' Contributions
Concept, Design, Writing and Literature Search: Huseyin Anil Korkmaz, Behzat Ozkan; Data Analysis, Writing and Literature Search: Ved Bhushan Arya; Data Analysis: Ahmet Gönüllü, Fulya Coşkunol; Data collection, Literature research: Fulya Coşkunol. All authors have read and approved the final version of the manuscript, and agree to be accountable for the work.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Korkmaz, H.A., Arya, V.B., Gönüllü, A. et al. Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series. Pediatr Drugs 25, 595–601 (2023). https://doi.org/10.1007/s40272-023-00578-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-023-00578-7